A substantial number of older people, particularly women, could be classified as “at-risk” for frailty. Identifying and treating these individuals will help to prevent disability and chronic diseases among seniors.
The findings could have important implications regarding the provision of health care to older adults who may require a substantial treatment burden and that they may be treated in the absence of medical urgency.
Factors such as comorbidities, age, sex, and education influence a person's risk of frailty. In conclusion, individual and contextual factors must be taken into account for the development of frailty.
Frailty is associated with an increased risk of death. In men, frailty is associated with accelerated cognitive decline and increased disability in old age. Because the risks of frailty increase in relation to the number of chronic diseases, it is unclear what causes the progression toward frailty.
When older patients with multimorbidity receive care in the community, one in five elderly patients and more than four-fifths of elderly patients in long-term care would be classified as having one or more signs of frailty.
Frailty is highly prevalent in a general community setting and the underlying causes are not clear but are likely multifactorial. Frailty may present a target for interventions aiming to improve survivability. However, treatment should focus on preventing further decline.
There have been no medications that were found to be helpful for treating [frailty] with any of the medications discussed. There have also been no studies showing that the drugs can either prevent or treat frailty. Clinicians can only recommend that people have an [older person clinic] on a routine basis to check for other health problems that are not being treated efficiently enough and therefore are causing more of a frailty problem at a later date.
Frailty as assessed by the frailty scores of the FFI and IADL can identify older persons at an increased risk of being enrolled in clinical trials.
Side effects that were frequently reported in this study included dizziness, nausea, and vomiting. Although it is recommended to assess ambulation before the administration of antiemetic agents, caution should be exercised to prevent unnecessary or painful antiemetic application.
The average estimate is 70 and 67, for women and men respectively (Fig 2). The age at onset of frailty seems to have been underestimated, especially for men, as most studies reporting the age at onset of frailty were based on self-report and a much larger sample size would be needed to obtain sufficient statistical power.
Ambulation is an effective adjunct in reducing the frequency and duration of hospitalizations related to fall-related injuries when used as a part of a comprehensive geriatric intervention.
There are some important issues that are important to consider, which include, the patient's functional status, comorbidities of patient's co-morbidities, patient's functional abilities, gait velocity, and the type of gait velocity measurement. Gait velocity is a useful measurement tool for clinicians and researchers. For rehabilitation clinicians, it can help increase the efficiency of physical therapy interventions. However, it should not be the sole means of determining disability. As there are not many studies that have examined gait velocity, it is extremely crucial to determine functional status and functional abilities prior.